Meeting
2019 ASCO Annual Meeting
Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Updated results.
Authors
Andreas Nicholas Saltos
Department of Thoracic Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL
Andreas Nicholas Saltos , Tawee Tanvetyanon , Eric B. Haura , Ben C. Creelan , Scott Joseph Antonia , Michael Rahman Shafique , Hong Zheng , Wenjie Dai , Zhihua Chen , James Joseph Saller , Nishan Tchekmedyian , Kristen Goas , Ram Thapa , Theresa A. Boyle , Dung-Tsa Chen , Amer A Beg , Jhanelle Elaine Gray
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02638090
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9073)
DOI
10.1200/JCO.2019.37.15_suppl.9073
Abstract #
9073
Poster Bd #
396
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC).
First Author: Andreas Nicholas Saltos
First Author: Igor Tsaur
Poster
2024 ASCO Genitourinary Cancers Symposium
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
First Author: Michelle Hsu
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 1 trial of combined MEK, STAT3 and PD-1 inhibition in metastatic pancreatic ductal adenocarcinoma (PDAC).
First Author: Peter Joel Hosein